Castle Creek Raises $75 Million to Advance Gene Therapy Programs

March 25, 2020

Rare Daily Staff

Castle Creek Biosciences said it completed a $75 million financing that will be used to advance and expand its gene therapy pipeline and expand its manufacturing capacity.

Paragon Biosciences led a $55 million equity investment with participation from Fidelity Management & Research Company and Valor Equity Partners. In addition, Horizon Technology Finance Corporation provided a $20 million venture loan.

Castle Creek Biosciences most advanced product candidate is FCX-007, an experimental gene therapy in late-stage development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a severe skin disease characterized by very fragile skin that is prone to chronic blistering and wounds from normal friction or irritation.

RDEB impacts children from birth and has a high mortality rate. There are currently no approved treatment options for RDEB.

John Maslowski, Chief Executive Officer of Castle Creek Biosciences

Stay Connected

Facebook Twitter Instagram Youtube

Castle Creek Raises $75 Million to Advance Gene Therapy Programs

Related

Seamless Raises $25 Million in Seed Financing, Expands to U.S. to Advance Programmable Gene Editing Platform

LifeArc Invests $50 Million to Launch Rare Disease Research Centers

GeneDx Partners with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset

FDA Tells Abeona It Won’t Approve RDEB Cell Therapy without Additional CMC Information

EU Approves AstraZeneca’s Voydeya for PNH as Add-on

Sanofi Reports Experimental Therapy for Blood Disorder Met Phase 3 Endpoint

Ipsen Enters Collaboration with Skyhawk for RNA-Targeted Therapies for Neurological Diseases

Lexeo Enters Data Collaboration with Cornell to Accelerate Development of Gene Therapy for FA Cardiomyopathy

FDA Grants Breakthrough Therapy Designation for Kura’s Treatment for NPM1-Mutant AML

Stay Connected